Vicore Pharma Holding AB (publ) (OM: VICO)
Health Care · Biotechnology · SE
Skr9.00
-3.43% today · -22.5% 1Y
Vicore Pharma Holding AB (publ) (OM: VICO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $253.39M and employs 46 people.
Over the last twelve months the share price has lost 22.5%, trading between 8.56 and 18.24.
Tweenvest scores Vicore Pharma Holding AB (publ) across four factors: quality 39/100, value 36/100. Its strongest factor is quality.
VICO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $253.39M
- Revenue (TTM)
- $412.09K
- P/E
- —
- EPS
- -1.91
- Dividend yield
- —
- Beta (5Y)
- 0.09
- 52-week high
- Skr18.24
- 52-week low
- Skr8.56
- Avg volume (3M)
- —
- Shares outstanding
- 281.53M
- Employees
- 46
- Next earnings
- —
About Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ), a Gothenburg, Sweden-based company, specializes in the discovery and advancement of therapies for rare lung conditions. Its core pipeline features VP01, an orally administered small molecule currently in Phase II clinical trials for indications such as interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19. The company is also progressing VP02, a novel formulation and delivery approach for an established immunomodulatory compound, which is in preclinical development for treating IPF. Vicore maintains strategic alliances, including a development cooperation with Emeriti Bio AB, a licensing arrangement with Nanologica AB (publ), and a collaboration with Alex Therapeutics AB focused on creating and clinically validating a digital therapeutic (DTx) built on the Alex DTx platform. Established in 2000, the company was formerly known as Mintage Scientific AB.
- ISIN
- SE0007577895
- Founded
- 2000
- Listed since
- Dec 10, 2015
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PharmaEngine, Inc.TPEX: 4162 | $257.02M | NT$57.20 | +3.25% |
| Immuneering CorporationNasdaqGM: IMRX | $254.91M | $3.94 | -3.19% |
| Amarin Corporation plcNasdaqCM: AMRN | $254.11M | $12.03 | -2.59% |
| Intelligene Inc.TPEX: 7832 | $253.95M | NT$14.00 | +2.56% |
| Adimmune CorporationTWSE: 4142 | $253.10M | NT$19.20 | +6.67% |
| Lineage Cell Therapeutics, Inc.NYSEAM: LCTX | $251.39M | $0.99 | +6.85% |
| TriSalus Life Sciences, Inc.NasdaqGM: TLSI | $249.99M | $4.06 | -6.02% |
| Zentalis Pharmaceuticals, Inc.NasdaqGM: ZNTL | $249.93M | $2.64 | +4.76% |
Figures last refreshed Oct 11, 2026.